Scientists developed a new drug that successfully targets the previously undruggable KRAS mutation which drives most pancreatic cancers nearly doubling patient survival in trials.
Tag: Daraxonrasib
New Drug Daraxonrasib Cracks Undruggable Pancreatic Cancer Target and Nearly Doubles Survival
A new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time